Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal

被引:87
作者
Kanwar, Jagat R. [1 ]
Sun, Xueying [2 ,3 ]
Punj, Vasu [4 ,5 ]
Sriramoju, Bhasker [1 ]
Mohan, Rajiv R. [6 ,7 ]
Zhou, Shu-Feng [8 ]
Chauhan, Ashok [9 ]
Kanwar, Rupinder K. [1 ]
机构
[1] Deakin Univ, LIMBR, Ctr Biotechnol & Interdisciplinary Biosci BioDeak, ITRI, Geelong, Vic 3217, Australia
[2] Harbin Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hepatosplen Surg Ctr, Harbin, Peoples R China
[3] Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1, New Zealand
[4] Univ So Calif, Keck Sch Med, USC Epigenome Ctr, Los Angeles, CA 90033 USA
[5] Univ So Calif, Keck Sch Med, Div Hematol, Los Angeles, CA 90033 USA
[6] Univ Missouri, Mason Eye Inst, Columbia, MO USA
[7] Harry S Truman Mem Vet Hosp, Columbia, MO 65201 USA
[8] Univ S Florida, Dept Pharmaceut Sci, Coll Pharm, Tampa, FL USA
[9] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, Columbia, SC USA
关键词
Nanoparticles; Blood-brain barrier; Neurological diseases; BLOOD-BRAIN-BARRIER; CONJUGATED PEGYLATED NANOPARTICLES; LOCKED NUCLEIC-ACIDS; DRUG-DELIVERY; ALZHEIMERS-DISEASE; IN-VITRO; NEURODEGENERATIVE DISORDERS; PARKINSONS-DISEASE; TARGETED DELIVERY; POLY(N-BUTYLCYANOACRYLATE) NANOPARTICLES;
D O I
10.1016/j.nano.2011.08.006
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
The incidence of neurological diseases of unknown etiology is increasing, including well-studied diseases such as Alzhiemer's, Parkinson's, and multiple sclerosis. The blood-brain barrier provides protection for the brain but also hinders the treatment and diagnosis of these neurological diseases, because the drugs must cross the blood-brain barrier to reach the lesions. Thus, attention has turned to developing novel and effective delivery systems that are capable of carrying drug and that provide good bioavailability in the brain. Nanoneurotechnology, particularly application of nanoparticles in drug delivery, has provided promising answers to some of these issues in recent years. Here we review the recent advances in the understanding of several common forms of neurological diseases and particularly the applications of nanoparticles to treat and diagnose them. In addition, we discuss the integration of bioinformatics and modern genomic approaches in the development of nanoparticles. From the Clinical Editor: In this review paper, applications of nanotechnology-based diagnostic methods and therapeutic modalities are discussed addressing a variety of neurological disorders, with special attention to blood-brain barrier delivery methods. These novel nanomedicine approaches are expected to revolutionize several aspects of clinical neurology. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:399 / 414
页数:16
相关论文
共 136 条
[21]   Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice [J].
Cherny, RA ;
Atwood, CS ;
Xilinas, ME ;
Gray, DN ;
Jones, WD ;
McLean, CA ;
Barnham, KJ ;
Volitakis, I ;
Fraser, FW ;
Kim, YS ;
Huang, XD ;
Goldstein, LE ;
Moir, RD ;
Lim, JT ;
Beyreuther, K ;
Zheng, H ;
Tanzi, RE ;
Masters, CL ;
Bush, AI .
NEURON, 2001, 30 (03) :665-676
[22]   Diabetic retinopathy [J].
Cheung, Ning ;
Mitchell, Paul ;
Wong, Tien Yin .
LANCET, 2010, 376 (9735) :124-136
[23]   Photothermal Efficiencies of Nanoshells and Nanorods for Clinical Therapeutic Applications [J].
Cole, Joseph R. ;
Mirin, Nikolay A. ;
Knight, Mark W. ;
Goodrich, Glenn P. ;
Halas, Naomi J. .
JOURNAL OF PHYSICAL CHEMISTRY C, 2009, 113 (28) :12090-12094
[24]   Multiple sclerosis [J].
Compston, A ;
Coles, A .
LANCET, 2002, 359 (9313) :1221-1231
[25]   Transfection of tyrosine kinase deleted FGF receptor-1 into rat brain substantia nigra reduces the number of tyrosine hydroxylase expressing neurons and decreases concentration levels of striatal dopamine [J].
Corso, TD ;
Torres, G ;
Goulah, C ;
Roy, I ;
Gambino, AS ;
Nayda, J ;
Buckley, T ;
Stachowiak, EK ;
Bergey, EJ ;
Pudavar, H ;
Dutta, P ;
Bloom, DC ;
Bowers, WJ ;
Stachowiak, MK .
MOLECULAR BRAIN RESEARCH, 2005, 139 (02) :361-366
[26]   Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer's and other CNS diseases [J].
Cui, ZR ;
Lockman, PR ;
Atwood, CS ;
Hsu, CH ;
Gupte, A ;
Allen, DD ;
Mumper, RJ .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2005, 59 (02) :263-272
[27]   Alzheimer's disease - Etiologies, pathophysiology, cognitive reserve, and treatment opportunities [J].
Cummings, JL ;
Vinters, HV ;
Cole, GM ;
Khachaturian, ZS .
NEUROLOGY, 1998, 51 (01) :S2-S17
[28]  
D'Aquino R, 2006, CHEM ENG PROG, V102, P35
[29]   Nanoinformatics: New Challenges for Biomedical Informatics at the Nano Level [J].
de la Iglesia, Diana ;
Chiesa, Stefano ;
Kern, Josipa ;
Maojo, Victor ;
Martin-Sanchez, Fernando ;
Potamias, George ;
Moustakis, Vassilis ;
Mitchell, Joyce A. .
MEDICAL INFORMATICS IN A UNITED AND HEALTHY EUROPE, 2009, 150 :987-991
[30]   Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly People [J].
De Meyer, Geert ;
Shapiro, Fred ;
Vanderstichele, Hugo ;
Vanmechelen, Eugeen ;
Engelborghs, Sebastiaan ;
De Deyn, Peter Paul ;
Coart, Els ;
Hansson, Oskar ;
Minthon, Lennart ;
Zetterberg, Henrik ;
Blennow, Kaj ;
Shaw, Leslie ;
Trojanowski, John Q. .
ARCHIVES OF NEUROLOGY, 2010, 67 (08) :949-956